Publications
Publications
Show Results For
-
All HBS Web
(10,047)
- Faculty Publications (842)
Page 1 of
842
Results
→
- February 2021
- Article
Platform Diffusion at Temporary Gatherings: Social Coordination and Ecosystem Emergence
By: Tommy Pan Fang, Andy Wu and David R. Clough
Software platforms create value by cultivating an ecosystem of complementary products and services. Existing explanations for how a prospective complementor chooses platforms to join assume the complementor has rich information about the range of available platforms....
View Details
Keywords:
Innovation Ecosystems;
Technology Diffusion;
Hackathon;
Contagion;
Software Applications;
Software Development;
Software Engineering;
Technology Strategy;
Technology Adoption;
Technological Innovation;
Technology Platform;
Technology Networks;
Innovation Strategy;
Multi-sided Platforms;
Network Effects;
Software;
Information Technology;
Technology Industry;
Computer Industry;
Information Technology Industry;
Video Game Industry
- 2021
- Article
The Sustainable Corporate Governance Initiative in Europe
By: Mark Roe, Holger Spamann, Jesse M. Fried and Charles C.Y. Wang
In July 2020, the European Commission published the “Study on directors’ duties and sustainable corporate governance” by EY. The Report purports to find evidence of debilitating short-termism in EU corporate governance and recommends many changes to support sustainable...
View Details
- 2021
- Working Paper
Private and Social Returns to R&D: Drug Development and Demographics
By: Efraim Benmelech, Janice Eberly, Dimitris Papanikolaou and Joshua Krieger
Investment in intangible capital—in particular, research and development—increased dramatically since the 1990s. However, output and measured productivity growth remains sluggish in recent years. One potential reason is that a significant share of the increase in...
View Details
- January 28, 2021
- Other Article
Lessons from the U.S.'s Rocky Vaccine Rollout
By: Robert S. Huckman and Bradley R. Staats
The rocky rollout of the COVID-19 vaccines is emblematic of many of the problems with the U.S. health care system. The United States is blessed with highly trained, excellent, and compassionate care providers and terrific research and development that has led to novel...
View Details
- January 2021
- Case
Aptiv PLC Board of Directors (A)
By: Lynn S. Paine and Will Hurwitz
Aptiv’s board must decide whether a joint venture with an auto maker is the right next step in the company’s efforts to develop and commercialize a production-ready autonomous driving system. While many commentators believed that Aptiv’s self-driving technologies had...
View Details
Keywords:
Automotive Industry;
Bankruptcy Reorganization;
Board Of Directors;
Board Committees;
Board Decisions;
Board Dynamics;
Corporate Boards;
Innovation And Strategy;
Legal Aspects Of Business;
Spin Off;
Strategic Alliances;
Strategic Change;
Strategic Evolution;
Supplier Relationships;
Technological Change;
Corporate Governance;
Governing And Advisory Boards;
Innovation Strategy;
Going Public;
Joint Ventures;
Leadership;
Restructuring;
Technological Innovation;
Transformation;
Auto Industry;
Europe;
United States
- Winter 2021
- Article
Dealmaking Disrupted: The Unexplored Power of Social Media in Negotiation
By: James K. Sebenius, Ben Cook, David A. Lax, Isaac Silberberg and Paul Levy
While social media has had profound effects in many realms, the theory and practice of negotiation have remained relatively untouched by this potent phenomenon. In this article, we survey existing research in this area and develop a broader framework for understanding...
View Details
- December 2020 (Revised February 2021)
- Case
IBM Watson at MD Anderson Cancer Center
By: Shane Greenstein, Mel Martin and Sarkis Agaian
After discovering that their cancer diagnostic tool, designed to leverage the cloud computing power of IBM Watson, needed greater integration into the clinical processes at the MD Anderson Cancer Center, the development team had difficult choices to make. The Oncology...
View Details
Keywords:
Decision Making;
Innovation Strategy;
Knowledge Management;
Knowledge Use And Leverage;
Operations;
Failure;
Technology;
Information Technology;
Software;
Health Care And Treatment;
Product development;
Health Industry;
Information Technology Industry;
Technology Industry;
United States;
Houston;
Texas
- December 2020
- Teaching Note
Forecasting ClimaCell
By: Joshua Lev Krieger, Christopher Stanton and James Barnett
A weather technology startup, ClimaCell considers the R&D trade-offs and financing implications of pursuing a proposed contract with a major automobile maker, rather than continuing its focus on building a scalable, all-purpose weather prediction engine.
View Details
- 2020
- Working Paper
Aggregate Advertising Expenditure in the U.S. Economy: What's Up? Is It Real?
By: Alvin J. Silk and Ernst R. Berndt
The two components of the advertising industry—the creative sector that develops and produces messages, and the communications sector that transmits messages via various media—have each been greatly affected by advances in creative design and communications...
View Details
- November 2020
- Teaching Note
DayTwo: Going to Market with Gut Microbiome
By: Ayelet Israeli
Teaching Note for HBS Case No. 519-010. DayTwo is a young Israeli startup that applies research on the gut microbiome and machine learning algorithms to deliver personalized nutritional recommendations to its users in order to minimize blood sugar spikes after meals....
View Details
Keywords:
Start-up Growth;
Startup;
Positioning;
Targeting;
Go To Market Strategy;
B2b Vs. B2c;
B2b2c;
Health ＆ Wellness;
Ai;
Machine Learning;
Female Ceo;
Female Protagonist;
Science-based;
Science And Technology Studies;
Ecommerce;
Applications;
Dtc;
Direct To Consumer Marketing;
Us Health Care;
＂usa,＂;
Innovation;
Pricing;
Business Growth;
Segmentation;
Distribution Channels;
Growth And development Strategy;
Business Startups;
Science-based Business;
Health;
Innovation And Invention;
Marketing;
Technology;
Business Growth And Maturation;
Health Industry;
Technology Industry;
Insurance Industry;
Information Technology Industry;
Food And Beverage Industry;
Israel;
United States
- 2020
- Chapter
The Group Malleability Intervention: Addressing Intergroup Conflicts by Changing Perceptions of Outgroup Malleability
By: Amit Goldenberg, J. J. Gross and Eran Halperin
Precise shifts in the ways people make sense of themselves, others, and social situations can help people flourish. This compelling handbook synthesizes the growing body of research on wise interventions—brief, nonclinical strategies that are "wise" to the impact of...
View Details
- October 2020
- Teaching Plan
Merck: COVID-19 Vaccines
By: Willy C. Shih
COVID-19 infections were still climbing across the U.S. and many other parts of the world in September 2020, and it seemed that every time Ken Frazier, the CEO of Merck & Co. consented to an interview in recent months he always seemed to hear the same question,...
View Details
- October 5, 2020
- Editorial
Robots Save Us Time—But Do They Make Us Happier?
By: A.V. Whillans, Emanuel de Bellis, Fabian Nindl and Tobias Schlager
Autonomous products such as robotic vacuum cleaners, lawn mowers, and playmates for our pets are meant to improve people’s lives—but do they actually make consumers happier? The authors share the results of recent research which found that owning autonomous products...
View Details
- 2020
- Working Paper
Estimating Causal Effects in the Presence of Partial Interference Using Multivariate Bayesian Structural Time Series Models
By: Fiammetta Menchetti and Iavor Bojinov
Researchers regularly use synthetic control methods for estimating causal effects when a sub-set of units receive a single persistent treatment, and the rest are unaffected by the change. In many applications, however, units not assigned to treatment are nevertheless...
View Details
- 2020
- Book
China and Europe on the New Silk Road: Connecting Universities Across Eurasia
By: Marijk C. van der Wende, William C. Kirby, Nian Cai Liu and Simon Marginson
The global order, based on international governance and multilateral trade mechanisms in the aftermath of the Second World War, is changing rapidly and creating waves of uncertainty. This is especially true in higher education, a field increasingly built on...
View Details
- September 2020
- Case
Disrupting Justice at RightNow: Rich or King
By: Shikhar Ghosh and Amir Reza Rezvani
The case examines issues such as cascading problems within the organization, changing founder roles, founder success criteria, as well as company exit consideration. In 2017, Dr. Torben Antretter, a former competitive tennis player and academic researcher, founded...
View Details
- September 2020 (Revised October 2020)
- Case
Moderna (A)
By: Marco Iansiti, Karim R. Lakhani, Hannah Mayer and Kerry Herman
In summer 2020, Stephane Bancel, CEO of biotech firm Moderna, faces several challenges as his company races to develop a vaccine for COVID-19. The case explores how a company builds a digital organization, and leverages artificial intelligence and other digital...
View Details
- 2020
- Working Paper
Chimeric Antigen Receptor (CAR) T-Cell Therapy: Case Histories of Significant Medical Advances
By: Amar Bhidé and Srikant M. Datar
In 2017, the US Food and Drug Administration (FDA) approved an immunotherapeutic treatment, called CAR-T therapy, for two kinds of blood cancers—acute leukemia (ALL) and a lymphoma. We describe 1) how CAR-T works; 2) the foundational advances and discoveries; 3)...
View Details
- September 2020
- Case
Minerva 2004: Discovery
By: John R. Wells and Benjamin Weinstock
After nearly five years in operation, Doctor Cynthia Bamdad, founder and CEO of Minerva Biotechnologies Corporation (Minerva), was reflecting on the company’s next steps. In a few short years, she and her small team had managed to develop a nanoparticle process for...
View Details
- September 2020
- Case
Minerva 2010: Turbulent Times
By: John R. Wells and Benjamin Weinstock
In 2010, amid a flurry of new discoveries, Cynthia Bamdad, founder and CEO of Minerva Biotechnologies Corporation (Minerva), raised $6.6 million to test her new cancer drugs in mice. It had been more than 6 years since she had announced that she and her small team at...
View Details